Therefore, despite the initial effective tumour response to neoadjuvant AIs in the majority of patients with ER+/HER2+ disease, continued proliferation could hint early resistance that may occur at later times in the clinical course of the disease. The gene discussed is ERBB2; the disease is neoplasm.